Alzheimer’s community awaits FDA vote on Biogen’s Aducanumab

CNBC’s Meg Tirrell joins ‘The News with Shepard Smith’ to discuss Biogen’s Alzheimer’s drug Aducanumab as patients await its FDA approval. The FDA will issue the decision by June 7. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

» Subscribe to CNBC TV:
» Subscribe to CNBC:
» Subscribe to CNBC Classic:

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

Connect with CNBC News Online
Get the latest news:
Follow CNBC on LinkedIn:
Follow CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Instagram:


Originally published here

The post Alzheimer's community awaits FDA vote on Biogen's Aducanumab first appeared on .

Health News - originally published at Health News -

This news story originally appeared at Health News - on 21 April 2022